Palbociclib in real clinical practice: Results of a single-center observational study DOI Creative Commons
А. В. Султанбаев, I. V. Kolyadina, А. Ф. Насретдинов

et al.

Meditsinskiy sovet = Medical Council, Journal Year: 2024, Volume and Issue: 21, P. 42 - 50

Published: Dec. 21, 2024

Introduction. A breakthrough in the treatment of metastatic hormone-dependent (HR+) breast cancer was combination endocrine therapy with CDK4/6 inhibitors, which significantly prolonged tumor response time to and median survival before progression. The effectiveness real-life practice is particular interest due wider population patients different somatic status comorbidity, often not included randomized trials. Aim. Analyze palbociclib using for treating HR+/HER2– advanced (mBC) at Republican Clinical Oncology Dispensary. Materials methods. Data from 323 were analyzed. Our study examined HR+ HER2– cancer. on clinicopathological characteristics disease progression during administration obtained by reviewing clinical data patient records radiological/pathological examination reports. Results. age 62 years. When assessing antitumor response, a partial recorded 54 (16.7%), stabilization 212 (65.6%), 57 (17.8%). progression-free 13 months. Grade 3 adverse events noted 23 patients: neutropenia 21.7% cases, hepatotoxicity 47.8% cardiotoxicity 17.4% coagulopathy 4.3%. No discontinued events. best results achieved who used an partner as first line stage. Conclusion. This analysis real-world use confirms RCT efficacy safety inhibitors HER2- mBC.

Language: Английский

Impact of Patient Profile on CDK4/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis DOI Open Access
Ioana-Miruna Stanciu,

Maria-Cristina Orlov-Slavu,

Andreea-Ioana Parosanu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3357 - 3357

Published: April 3, 2025

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have transformed the treatment landscape for patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer. However, their efficacy is influenced by various clinical biological factors, including patient age, tumor biology, treatment-related toxicities. The aim of this study to evaluate impact demographic, clinical, tumor-related characteristics on CDK4/6 in a cohort metastatic HR+/HER2- We conducted retrospective analyzing outcomes 95 ER-positive, HER2-negative cancer (BC) treated (ribociclib, palbociclib, abemaciclib) combination endocrine therapy. demographics, characteristics, regimens were examined, primary focus progression-free survival (PFS), overall (OS), time (TOT), influence factors. Younger (under 50 years) demonstrated higher aggressiveness, reflected Ki67 levels histological grades, which negatively impacted outcomes. Ribociclib was associated highest benefit, particularly younger patients. Older (over showed greater rates comorbidities toxicity, dose reductions correlated improved This highlights significance personalized strategies based comorbidities, biology. shows superior younger, less comorbid patients, while palbociclib remains viable option older comorbidity burdens.

Language: Английский

Citations

0
Palbociclib in real clinical practice: Results of a single-center observational study DOI Creative Commons
А. В. Султанбаев, I. V. Kolyadina, А. Ф. Насретдинов

et al.

Meditsinskiy sovet = Medical Council, Journal Year: 2024, Volume and Issue: 21, P. 42 - 50

Published: Dec. 21, 2024

Introduction. A breakthrough in the treatment of metastatic hormone-dependent (HR+) breast cancer was combination endocrine therapy with CDK4/6 inhibitors, which significantly prolonged tumor response time to and median survival before progression. The effectiveness real-life practice is particular interest due wider population patients different somatic status comorbidity, often not included randomized trials. Aim. Analyze palbociclib using for treating HR+/HER2– advanced (mBC) at Republican Clinical Oncology Dispensary. Materials methods. Data from 323 were analyzed. Our study examined HR+ HER2– cancer. on clinicopathological characteristics disease progression during administration obtained by reviewing clinical data patient records radiological/pathological examination reports. Results. age 62 years. When assessing antitumor response, a partial recorded 54 (16.7%), stabilization 212 (65.6%), 57 (17.8%). progression-free 13 months. Grade 3 adverse events noted 23 patients: neutropenia 21.7% cases, hepatotoxicity 47.8% cardiotoxicity 17.4% coagulopathy 4.3%. No discontinued events. best results achieved who used an partner as first line stage. Conclusion. This analysis real-world use confirms RCT efficacy safety inhibitors HER2- mBC.

Language: Английский

Citations

0